Psychiatric Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearables, Mobile-based Applications, Sensors), By Clinical Practice (Diagnostic, Monitoring, Predictive & Prognostic), By End-use, By Region, And Segment Forecasts, 2025

Psychiatric Digital Biomarkers Market Trends

The global psychiatric digital biomarkers market size was estimated at USD 631.3 million in 2024 and is projected to grow at a CAGR of 24.4% from 2025 to 2030. The rising prevalence of mental health disorders, advancements in digital health technologies, and growing demand for personalized medicine drive the market. For instance, according to the World Health Organization, approximately 280 million individuals across the globe have depression. Depression is about 50% more common among women than men.

The rising adoption of wearable devices and mobile health apps in mental healthcare contributes to market growth. Moreover, according to the International Data Corporation (IDC), shipments of wearable devices increased by 2.6% across the globe in the third quarter of 2023 compared to the previous year, setting a new third-quarter record with a total of 148.4 million units.

Moreover, the global burden of mental health disorders is on the rise, with conditions such as depression, anxiety, bipolar disorder, and schizophrenia affecting millions of individuals worldwide. In 2023, Mental Health America, Inc. found that 20.17% of youths aged 12-17 had encountered a major depressive episode, with 15% suffering severe impairment affecting daily activities. This increasing prevalence is driving the need for more effective tools to monitor and manage mental health conditions, leading to a growing demand for psychiatric digital biomarkers.

Technological advancements in digital health technologies have revolutionized the field of mental healthcare. Innovations such as artificial intelligence (AI), machine learning, and data analytics enable the development of sophisticated digital biomarkers that provide valuable insights into an individual’s mental health status. AI-powered algorithms analyze data from smartphone sensors to detect changes in behavior patterns that indicate early signs of a mental health crisis. For instance, in September 2022, Feel Therapeutics Inc., a digital biomarkers and therapeutics developer to bring objective data in mental health, introduced the Digital Precision Medicine Platform. With this platform, the company is able to collect clinically valuable data points passively and on a 24/7 basis to generate real-world evidence (RWE) and discover novel digital biomarkers and endpoints.

Global Psychiatric Digital Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global psychiatric digital biomarkers market report based on type, clinical practice, end-use, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Wearable
• Mobile based Applications
• Sensors
• Others
• Clinical Practice Outlook (Revenue, USD Million, 2018 - 2030)
• Diagnostic Psychiatric Digital Biomarkers
• Monitoring Psychiatric Digital Biomarkers
• Predictive and Prognostic Psychiatric Digital Biomarkers
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Healthcare companies
• Healthcare Providers
• Payers
• Others (Patient, caregivers)
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

• Latin America

Brazil

Argentina

• MEA

South Africa

Saudi Arabia

UAE

Kuwait